GeneDx is trading 9.73% higher at $61.62, rebounding after October 23; no clear company-specific catalyst is identified for the October 26 move.
- October 23 close: $56.15, after a 16.37% decline; positioning after the sharp prior-session sell-off may explain the rebound, but is unconfirmed.
- Q3 2026 results are scheduled for November 9 after market close, not October 26.
- Major indices are up, but each remains below the supplied 0.5% threshold to attribute the move to broad market sentiment.